Wellington Management Group LLP Acquires 178,078 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

Wellington Management Group LLP boosted its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 20.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,061,299 shares of the company's stock after acquiring an additional 178,078 shares during the period. Wellington Management Group LLP owned approximately 4.38% of OrthoPediatrics worth $24,601,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of OrthoPediatrics during the 3rd quarter valued at about $25,000. Rhumbline Advisers raised its holdings in shares of OrthoPediatrics by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock worth $612,000 after buying an additional 1,042 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of OrthoPediatrics by 125.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock worth $94,000 after buying an additional 1,929 shares during the period. R Squared Ltd acquired a new stake in OrthoPediatrics in the 4th quarter valued at $48,000. Finally, Bank of New York Mellon Corp grew its position in OrthoPediatrics by 3.8% in the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company's stock valued at $1,338,000 after acquiring an additional 2,099 shares during the period. Institutional investors and hedge funds own 69.05% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on KIDS. Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 price objective for the company. Truist Financial reduced their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research report on Friday. Stifel Nicolaus dropped their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.00.

Remove Ads

OrthoPediatrics Trading Down 1.1 %

OrthoPediatrics stock traded down $0.23 during trading hours on Friday, reaching $21.16. 142,007 shares of the company's stock traded hands, compared to its average volume of 200,282. OrthoPediatrics Corp. has a fifty-two week low of $20.78 and a fifty-two week high of $35.99. The firm's 50 day moving average is $24.14 and its 200-day moving average is $24.73. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a market capitalization of $513.91 million, a price-to-earnings ratio of -17.20 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The firm had revenue of $52.67 million for the quarter, compared to analysts' expectations of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same period last year, the firm earned ($0.23) earnings per share. On average, analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insider Transactions at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company's stock, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. The trade was a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is currently owned by company insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.